地塞米松联合氨甲环酸治疗前列腺增生术后出血致纤溶亢进患者的临床研究  

Clinical trial of dexamethasone combined with tranexamic acid in the treatment of patients with postoperative bleeding induced fibrinolysis in benign prostatic hyperplasia

作　　者：刘兆月 严慧芳 靳珊珊 LIU Zhao-yue;YAN Hui-fang;JIN Shan-shan(Department of Urology,Hengshui People's Hospital,Hengshui 053000,Hebei Province,China;Department of Pediatric Internal Medicine,Hengshui People's Hospital,Hengshui 053000,Hebei Province,China)

机构地区：[1]衡水市人民医院泌尿外科,河北衡水053000 [2]衡水市人民医院小儿内科,河北衡水053000

出　　处：《中国临床药理学杂志》2025年第1期16-20,共5页The Chinese Journal of Clinical Pharmacology

基　　金：河北省卫健委基金资助项目(20181570)。

摘　　要：目的观察地塞米松注射液联合氨甲环酸注射液治疗前列腺增生术后出血致纤溶亢进患者的临床疗效及安全性。方法将前列腺增生术后出血致纤溶亢进患者随机分为对照组和试验组。对照组给予氨甲环酸1g·d^(-1),静脉滴注;试验组在对照组治疗的基础上,给予地塞米松10 mg,静脉推注,q12h。2组患者均连续治疗5d。比较2组患者的临床疗效、凝血因子水平、生活质量(QOL)评分、国际前列腺症状评分(IPSS),并进行安全性分析。结果试验组入组52例,脱落2例,最终有50例纳入统计分析;对照组入组51例,脱落1例,最终有50例纳入统计分析。治疗后,试验组和对照组的总有效率分别为94.00%(47例/50例)和72.00%(36例/50例),在统计学上差异有统计学意义(P<0.05)。治疗后,试验组和对照组的部分凝血活酶时间分别为(35.12±4.38)和(49.14±5.61)s,凝血酶原时间分别为(12.78±1.67)和(16.10±1.94)s,D-二聚体水平分别为(350.42±25.90)和(380.90±37.10)μg·L^(-1),QOL评分分别为(1.16±0.37)和(2.26±0.78)分,IPSS分别为(4.48±1.22)和(16.12±3.67)分,在统计学上差异均有统计学意义(均P<0.05)。2组患者的药物不良反应均以腹痛、贫血、头痛为主。试验组和对照组的总药物不良反应发生率分别为6.00%和16.00%,在统计学上差异无统计学意义(P>0.05)。结论地塞米松注射液联合氨甲环酸注射液治疗前列腺增生术后出血致纤溶亢进患者的临床疗效确切,其能够显著改善患者的凝血功能,缓解症状,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of dexamethasone injection combined with tranexamic acid injection in the treatment of patients with hyperfibrinolysis caused by bleeding after prostatic hyperplasia.Methods Patients with hyperfibrinolysis caused by hemorrhage after prostatic hyperplasia were randomly divided into control group and treatment group.The control group was given 1 g·d^(-1)tranexamic acid intravenously.On the basis of the control group,the treatment group was given dexamethasone 10 mg,intravenous injection,q12 h.Both groups were treated continuously for 5 days.The clinical efficacy,coagulation factor level,quality of life(QOL)score,international prostate symptom score(IPSS),and safety were compared between the two groups.Results In the treatment group,52 cases were enrolled,2 cases fell off,and finally 50 cases were included in the statistical analysis.In the control group,51 cases were enrolled,1 case fell off,and finally 50 cases were included in the statistical analysis.After treatment,the total effective rates of treatment group and control group were 94.00%(47 cases/50 cases)and 72.00%(36 cases/50 cases),respectively,and the difference was statistically significant(P<0.05).After treatment,the partial thromboplastin time of treatment group and control group were(35.12±4.38)and(49.14±5.61)s;the prothrombin time were(12.78±1.67)and(16.10±1.94)s;D-dimer levels were(350.42±25.90)and(380.90±37.10)μg·L^(-1);Q0L scores were(1.16±0.37)and(2.26±0.78)points,IPSS were(4.48±1.22)and(16.12±3.67)points,respectively.The differences of above indexes were statistically significant between two groups(all P<0.05).The adverse drug reactions of two groups were mainly abdominal pain,anemia and headache.The incidences of total adverse drug reactions in treatment group and control group were 6.00% and 16.00%,respectively,without statistical significance(P>0.05).Conclusion Dexamethasone injection combined with tranatemylic acid injection has a definitive clinical efficacy in the treatment

关 键 词：地塞米松注射液 氨甲环酸注射液 前列腺增生术 纤溶亢进 凝血因子 安全性评价 

分 类 号：R97[医药卫生—药品]